Can a simple cream shield cancer patients from radiation burns?
NCT ID NCT07492654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a cream called triethanolamine (Trolamine) can prevent or reduce vaginal inflammation caused by radiation therapy in cervical cancer patients. About 238 women will either use the cream daily during radiotherapy plus routine care, or receive routine care alone. Researchers will check for vaginitis severity and healing rates up to 90 days after treatment ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- triethanolamine cream (Trolamine/Biafine)
- What this could lead to
- If it works, this could offer a simple, low-cost way to prevent painful vaginal inflammation during radiation therapy for cervical cancer.
- What could go wrong
- This is a phase 4 trial, but it's not yet recruiting. The cream may not reduce vaginitis better than routine care, and side effects like irritation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment